Compare YHGJ & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHGJ | LYRA |
|---|---|---|
| Founded | 1975 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 7.6M |
| IPO Year | 1997 | 2020 |
| Metric | YHGJ | LYRA |
|---|---|---|
| Price | $4.18 | $3.76 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 16.7K | ★ 92.2K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,377,000.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $4.00 | $2.84 |
| 52 Week High | $12.70 | $37.50 |
| Indicator | YHGJ | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 39.75 |
| Support Level | $4.08 | $3.55 |
| Resistance Level | $5.43 | $4.25 |
| Average True Range (ATR) | 0.35 | 0.42 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 17.38 | 13.39 |
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.